164 related articles for article (PubMed ID: 9796983)
21. Genetic engineering of bovine Ig. Construction and characterization of hapten-binding bovine/murine chimeric IgE, IgA, IgG1, IgG2, and IgG3 molecules.
Knight KL; Suter M; Becker RS
J Immunol; 1988 May; 140(10):3654-9. PubMed ID: 3361125
[TBL] [Abstract][Full Text] [Related]
22. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
24. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
25. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.
Zalutsky MR; Moseley RP; Coakham HB; Coleman RE; Bigner DD
Cancer Res; 1989 May; 49(10):2807-13. PubMed ID: 2469537
[TBL] [Abstract][Full Text] [Related]
27. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
Buchsbaum DJ; Brubaker PG; Hanna DE; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z
Cancer Res; 1990 Feb; 50(3 Suppl):993s-999s. PubMed ID: 2297753
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
[TBL] [Abstract][Full Text] [Related]
29. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
30. A chimeric anti-CEA antibody with heavy interchain disulfide bonds deleted: molecular characterization and biodistributions in normal and tumor bearing mice.
Neumaier M; Gaida FJ; Lewis MR; Hefta LJ; Shively LE; Raubitschek A; Shively JE
Anticancer Res; 1999; 19(1A):13-21. PubMed ID: 10226519
[TBL] [Abstract][Full Text] [Related]
31. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
32. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
33. The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.
Colapinto EV; Lee YS; Humphrey PA; Zalutsky MR; Friedman HS; Bullard DE; Bigner DD
Br J Neurosurg; 1988; 2(2):179-91. PubMed ID: 3267302
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
35. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation.
Hauck ML; Zalutsky MR
Int J Hyperthermia; 2005 Feb; 21(1):13-27. PubMed ID: 15764348
[TBL] [Abstract][Full Text] [Related]
36. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
37. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.
Zalutsky MR; Stabin MG; Larsen RH; Bigner DD
Nucl Med Biol; 1997 Apr; 24(3):255-61. PubMed ID: 9228660
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis.
Bourdon MA; Coleman RE; Blasberg RG; Groothuis DR; Bigner DD
Anticancer Res; 1984; 4(3):133-40. PubMed ID: 6465851
[TBL] [Abstract][Full Text] [Related]
39. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
